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ABSTRACT
Transcranial sonography has become a useful tool in the differential 
diagnosis of parkinsonian syndromes. This is a non-invasive, low cost 
procedure. The main finding on transcranial sonography in patients 
with idiopathic Parkinson’s disease is an increased echogenicity of 
the mesencephalic substantia nigra region. This hyperechogenicity 
is present in more than 90% of cases, and reflects a dysfunction in 
the dopaminergic nigrostriatal pathway. This study discussed how 
the hyperechogenicity of the substantia nigra may facilitate the 
differential diagnosis of parkinsonian syndromes.
Keywords: Parkinson disease/ultrasonography; Ultrasonography, doppler, 
 transcranial; Diagnosis, differential 
RESUMO 
A ultrassonografia transcraniana tem se tornado ferramenta útil 
no diagnóstico diferencial das síndromes parkinsonianas. Trata-
se de um método não invasivo e de baixo custo. O principal 
achado da ultrassonografia transcraniana em pacientes com 
doença de Parkinson idiopática é o aumento da ecogenicidade, ou 
hiperecogenicidade, na região da substância negra mesencefálica, 
presente em mais de 90% dos casos, o que reflete disfunção da via 
dopaminérgica nigroestriatal. O presente trabalho abordou como a 
hiperecogenicidade da substância negra pode auxiliar no diagnóstico 
diferencial das síndromes parkinsonianas.
Descritores: Doença de Parkinson/ultrassonografia; Ultrassonografia 
doppler transcraniana; Diagnóstico diferencial
INTRODUCTION
Parkinson’s disease (PD) is a common neurodegenerative 
disease, clinically characterized by cog-wheel rigidity, 
rest tremor (most common sign), bradykinesia (most 
important and disabling sign) and postural instability 
(not associated with primary visual, cerebellar, 
proprioceptive or vestibular dysfunctions)(1). According 
to the United Kingdom Parkinson’s Disease Society 
Brain Bank,(2) the disease is suspected when bradykinesia 
is associated with at least one of the clinical signs 
described above, after the exclusion of several causes 
of parkinsonism. During the clinical follow-up of these 
patients at least three of the following criteria should 
be observed: unilateral onset, rest tremor, progressive 
disorder, persistent asymmetry affecting side of onset 
most, a satisfactory response to levodopa, levodopa 
response for 5 years or more, dyskinesia, and a clinical 
course of 10 years or more.
The prevalence of PD is estimated to be 150 to 200 
cases of the disease per 100,000 inhabitants. It may 
affect up to 3.3% of individuals older than 65 years. 
Early symptoms of PD before the sixth decade of life 
are uncommon(3). In Brazil, a study conducted in the city 
of Bambui (MG) revealed that among 1185 participants 
aged 63 years, 3.3% had PD(4).
Since its first description in 1817, by James Parkinson, 
the diagnosis of PD remains essentially clinical(5). The 
confirmation of the diagnosis by histopathological 
examination is based on the demonstration of a loss 
of neuromelanin-rich dopaminergic neurons in the 
substantia nigra (SN) pars compacta, in the midbrain, 
associated with the occurrence of eosinophilic 
cytoplasmic inclusions, known as Lewy bodies, in the 
remnants of the mesencephalic neurons(2,6). According 
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to histopathological studies, approximately 25% of 
individuals with a presumptive diagnosis of PD are 
misdiagnosed(5.6). When the diagnosis is determined 
by a neurologist specialized in movement disorders, this 
number decreases, but remains high (about 10%)(7,8). 
In most cases, these are not “error” diagnoses, but 
“uncertain” or “doubtful” diagnoses, especially in the 
early stages of the disease, when the signs and symptoms 
are still mild(9). Furthermore, many conditions can 
mimic idiopathic PD for years, such as atypical or 
secondary parkinsonian syndromes, essential tremor, 
and depression associated with motor slowing(8,10). The 
differentiation of diseases comprising the parkinsonian 
syndromes presents a challenge in clinical practice, 
even to those specialized in movement disorders. 
Characteristic signs of atypical parkinsonian syndromes, 
such as postural instability, vertical gaze palsy and 
signs of frontal lobe dysfunction, which are indicative 
of progressive supranuclear palsy (PSP), and significant 
autonomic dysfunction, which is suggestive of multiple 
system atrophy (MSA), commonly occur at later stages. 
On the other hand, characteristic signs of atypical 
parkinsonian syndromes, such as postural instability, 
signs of frontal lobe dysfunction and autonomic 
dysfunction may also be found in PD(10). In practice, in 
many cases it is not possible to distinguish the different 
diagnosis in the early stages considering only the clinical 
manifestations.
Computed tomography (CT) and magnetic resonance 
imaging (MRI) have been widely used in the 
investigation of patients with suspected PD. However, 
despite modern, these methods are not capable of 
detecting brain abnormalities that represent the 
histopathologic substrate of this disease. In clinical 
practice, these techniques have been indicated to rule 
out secondary causes of parkinsonism, such as ischemic 
or hemorrhagic strokes, hydrocephalus, brain tumors, 
among others. In more advanced stages of atypical 
parkinsonian syndromes, some MRI findings may help 
to discriminate between PD and MSA, such as atrophy 
of cerebellopontine (which may lead to a cross-shaped 
signal hyperintensity in the pons on the T2 sequence, 
or hot cross bun sign) and putamen fibers; between 
PD and PSP, such as frontal or brain stem atrophy; and 
between PD and corticobasal degeneration, such as 
predominantly unilateral cortical atrophy(11). Therefore, 
considering that the correct identification of these 
conditions is fundamentally important – PD has a better 
prognosis and responds satisfactorily to levodopa and 
neurosurgical treatment – the development of methods 
for demonstrating PD brain changes are needed to 
reduce diagnostic uncertainty and its socioeconomic 
impacts.
Transcranial sonography in Parkinson’s disease
In the late 1980s, new discoveries in neurosonology 
allowed the assessment of the echogenicity of deep brain 
structures, without the need for surgical opening of the 
skull, using transcranial sonography (TCS). The method 
was received with skepticism by the scientific community 
because it was difficult to understand how an “outdated” 
method based on properties of ultrasonography waves 
could reveal brain tissue abnormalities not demonstrable 
by advanced neuroimaging techniques. This is a 
noninvasive, painless, low cost exam, which is potentially 
available in developing countries, and which can be 
performed in patients with involuntary movements of 
the head, without anesthesia, because the artifacts 
resulting from the movements can be corrected by the 
physician during the procedure. 
The use of this technique relies on the principle 
that morphological and functional changes and the 
chemical composition of the brain structures associated 
with movement disorders can lead to changes in their 
echogenicity. This procedure has been considered 
sensitive and reliable in detecting abnormalities of the 
basal ganglia of the brain, such as degeneration of the 
SN in idiopathic PD, lesion of the lentiform nucleus in 
idiopathic dystonia, and degeneration of the SN and the 
caudate nucleus in Huntington’s disease, among others. 
The method is also useful in the differential diagnosis 
of movement disorders and to clarify some of their 
pathophysiological mechanisms(12-16).
Clinical significance of the hyperechogenicity of the 
substantia nigra
Mesencephalic SN hyperechogenicity, defined by 
most authors as an increased echogenic area in the SN 
region, was first described in 1995 by Becker et al. in 
individuals with idiopathic PD(17) (Figure 1). This signal 
occurs in the majority of patients with idiopathic PD 
(over 90%) and indicates functional impairment of the 
nigrostriatal dopaminergic system. It is believed to be 
caused by increased iron content in abnormal protein 
linkages in the SN region(18). It is not known, however, 
whether this increased amount of iron in this region is a 
primary cause of PD, which would cause oxidative stress 
and injury of dopaminergic neurons, or is a secondary 
phenomenon in the development of disease. In general, 
the SN hyperechogenicity is present bilaterally in PD, 
is more extensive (in terms of echogenic area) on the 
side contralateral to the more symptomatic side, is 
stable during the course of the disease, and is clinically 
associated with rigidity and bradykinesia(19, 20). Despite 
the controversies, some studies suggest that the larger 
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the echogenic area of the SN, the earlier the onset of 
PD and the slower the progression of the disease(21,22). 
This finding has been considered a biomarker for 
early diagnosis of PD and not a marker of disease 
progression(23).
On the other hand, the echogenicity of the SN 
can be found in about 10% of the healthy population. 
Studies with positron emission tomography (PET) 
and single photon emission computerized tomography 
(SPECT) using, respectively, 18F-Dopa and 123I-FP- 
CIT or [99mTc]-TRODAT-1 as markers of activity of 
the dopamine transporter molecule (DAT), revealed 
that, similarly to the SN hyperechogenicity found 
in PD, this finding is also associated with reduced 
activity of the nigrostriatal dopaminergic system, 
which is suggestive of impaired functional reserve of 
this neural system(18,24). The associations between SN 
hyperechogenicity and motor retardation in healthy 
elderly subjects and between SN hyperechogenicity and 
severity of symptoms associated with neuroleptic-induced 
parkinsonism have recently been demonstrated(25). 
Other conditions in which the hyperechogenicity of 
the SN occurs include: individuals with parkin gene 
mutation, corticobasal degeneration, dementia with 
Lewy bodies and spinocerebellar ataxias(13,26, 27).
Interpretation of the transcranial sonography findings 
in parkinsonian syndromes
In the management of patients with parkinsonian 
syndrome, brain ultrasonography findings should only 
be considered after receiving medical history and 
detailed neurological examination of the patients, 
and never used alone, for they must be analyzed 
in conjunction with clinical data. Essential tremor, 
depression, MSA, PSP, and corticobasal degeneration 
are the major disorders in which parkinsonian signs and 
symptoms may be present and in which TCS may be 
useful for differentiating these conditions(13).
Essential tremor
In the practice of medicine, when the clinical 
manifestations are not characteristic and/or the 
patient does not meet the clinical criteria for diagnosis 
of PD and essential tremor, the presence of SN 
hyperechogenicity does not rule out essential tremor, 
but it reinforces the diagnosis of PD. On the other 
hand, normal echogenicity in SN region favors the 
possibility of essential tremor. It is noteworthy that the 
prevalence of SN hyperechogenicity in subjects with 
essential tremor is two to four times higher than the 
prevalence of this sign in the healthy population, and 
patients with essential tremor have three times higher 
risk of developing PD. Further studies are needed 
to clarify whether the increased prevalence of SN 
hyperechogenicity in subjects with essential tremor 
may explain the higher frequency of conversion of this 
condition to PD. TCS has a sensitivity of 75-86%, a 
specificity of 84-93%, and a positive predictive value 
of 91-95% in differentiating between essential tremor 
and PD(13,24,28).
Depression
Approximately 10-45% of patients with PD may have 
associated depression(29). In addition, individuals with 
depression may present signs and symptoms that 
occur frequently in PD, including masking of facial 
expression, bradykinesia, hypophonia, apathy, motor 
retardation, cognitive dysfunction, and in some cases, 
increased muscle tone(29). The echogenicity of the SN 
can help distinguish between the two conditions: SN 
hyperechogenicity is generally associated with PD, but 
not with depression; in patients with depression and 
hyperechogenicity of the SN, the signs and symptoms 
of depression may be considered as pre-motor signs 
and symptoms of PD(30). Patients with depression are 
at greater risk (two to three times) of developing PD 
compared to the healthy population and, interestingly, 
the prevalence of SN hyperechogenicity in patients 
with depression is about three times higher than in the 
normal population(31). 
Figure 1. Transcranial sonography of a patient with Parkinson’s disease. Intense 
hyperechogenicity can be viewed in the region of the substantia nigra of the 
midbrain bilaterally (A and B). The hypoechogenic mesencephalon shows a 
butterfly shape and is surrounded by the hyperechogenic basal cisterns (C)
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The hypoechogenicity of the raphe nuclei of the 
brainstem is present in 50-70% of cases of unipolar 
depression, in 40 to 60% of patients with PD and 
depression, and in about 60% of patients with PD 
and urinary incontinence. When PD or depression is 
suspected, normal echogenicity of the SN coupled with 
hypoechogenicity of the raphe nuclei are indicative of 
unipolar depression(32).
Atypical parkinsonian syndromes
According to a prospective blinded study in which 
patients with diagnostic uncertainty due to mild and 
initial parkinsonism were followed until the definition 
of the diagnosis, SN hyperechogenicity was significantly 
predictive for the diagnosis of PD. In terms of early 
diagnosis of PD, both the sensitivity and the positive 
predictive value of SN hyperechogenicity were 94.9%, 
the specificity and the negative predictive value 
were both 85.7%, and the initial diagnostic accuracy 
compared to the final diagnosis was 92.4%. As to the 
early differential diagnosis between PD and atypical 
parkinsonian syndromes, the SN hyperechogenicity had 
a sensitivity of 94.8%, a specificity of 90%, a positive 
predictive value of 97.4%, a negative predictive value 
of 81.8%, and a diagnostic accuracy of 93.9%. As to the 
early differential of atypical parkinsonian syndromes, 
the finding of hyperechogenicity of the lentiform 
nucleus had a sensitivity of 66.7%, a specificity of 
68.6%, a positive predictive value of 35.3%, a negative 
predictive value of 88.9%, and a diagnosis accuracy of 
68.2%(33).
Studies conducted in patients in advanced stages 
of disease found that the hyperechogenicity of the SN 
can discriminate PD from MSA and PSP in more than 
90% of cases, because it occurs in most patients with 
PD and only in a minority of those with MSA and PSP. 
Furthermore, as the hyperechogenicity of the lenticular 
nucleus is described in 70-80% of individuals with MSA 
and PSP, but only in 10-25% of cases of PD, the joint 
evaluation of the echogenicity of the SN associated 
with the echogenicity of the lenticular nucleus can 
discriminate PD from MSA and PSP with a positive 
predictive value exceeding 90%(34).
Similar to PD, corticobasal degeneration is also 
associated with increased echogenicity of the SN: 
about 90% of patients with corticobasal degeneration 
present SN hyperechogenicity bilaterally. Although 
this fact limits the use of SN echogenicity to distinguish 
between the two conditions, it allows discrimination 
between MSA and corticobasal degeneration. As the 
enlargement of the third ventricle (distance between 
the walls>10mm) is common in patients with MSA, the 
hyperechogenicity of the SN associated with a distance 
between the third ventricle walls <10mm can distinguish 
between corticobasal degeneration and MSA, with a 
positive predictive value of more than 90%(34).
Future perspectives
There is strong evidence that SN hyperechogenicity 
associated with other pre-motor symptoms of PD 
can predict the risk of developing the disease. In fact, 
a recent and well conducted study showed that in 
patients with idiopathic REM sleep behavior disorder, 
decreased striatal dopamine transporter uptake and 
SN hyperechogenicity reflect a dysfunction of the 
nigrostriatal dopaminergic system and may be 
markers that identify individuals with increased risk 
of developing PD and dementia with Lewy bodies(35). 
Future studies should elucidate the value of SN 
hyperechogenicity in the determination of PD, in its 
preclinical phase.
CONCLUSION
Correct diagnosis of parkinsonian syndromes is relevant 
to the clinical and surgical treatment of patients. TCS 
plays an important role in this process and can be used 
in clinical routine. 
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